Stockscreener 앱 받기
40.86
0.63%
-0.26
시간 외 거래:
40.99
0.13
+0.32%
전일 마감가:
$41.12
열려 있는:
$40.8
하루 거래량:
1.05M
Relative Volume:
0.65
시가총액:
$2.71B
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-14.97
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
+2.41%
1개월 성능:
+7.75%
6개월 성능:
+187.54%
1년 성능:
+205.38%
1일 변동 폭
$39.61
$41.89
1주일 범위
$39.44
$43.43
52주 변동 폭
$8.241
$44.80
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
40.86 | 3.19B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Price action breakdown for Mineralys Therapeutics Inc.July 2025 Movers & Weekly Chart Analysis and Guides - newser.com
Mineralys Therapeutics Inc. stock trendline breakdownJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Heatmap analysis for Mineralys Therapeutics Inc. and competitors2025 Market Overview & Fast Moving Stock Watchlists - newser.com
Multi factor analysis applied to Mineralys Therapeutics Inc.July 2025 Setups & Low Risk Profit Maximizing Plans - newser.com
Jennison Associates LLC Sells 743,711 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
What moving averages say about Mineralys Therapeutics Inc.2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Why Mineralys Therapeutics Inc. stock is favored by top institutionsWatch List & Real-Time Buy Signal Alerts - newser.com
Will Mineralys Therapeutics Inc. stock remain a Wall Street favoriteOptions Play & Low Volatility Stock Recommendations - newser.com
Is Mineralys Therapeutics Inc. stock a dividend growth opportunity2025 Technical Patterns & High Accuracy Swing Entry Alerts - newser.com
How Mineralys Therapeutics Inc. stock reacts to Fed rate cutsRate Hike & High Return Stock Watch Alerts - newser.com
Real time scanner hits for Mineralys Therapeutics Inc. explained2025 Year in Review & Real-Time Buy Zone Alerts - newser.com
Has Mineralys Therapeutics Inc. found a price floorQuarterly Earnings Summary & Short-Term High Return Strategies - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $52.00 - MarketBeat
Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC), Thermo Fisher (TMO) and Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
Will Mineralys Therapeutics Inc. stock maintain growth storyBuy Signal & Community Verified Trade Alerts - newser.com
Mineralys Therapeutics to Present Key Lorundrostat Data at ASN Kidney Week 2025 - MSN
Is Mineralys Therapeutics Inc a good long term investmentMarket Breadth Indicators & Free High Velocity Capital Growth - earlytimes.in
Ranking Mineralys Therapeutics Inc. among high performing stocks via toolsMarket Trend Review & Verified Technical Signals - newser.com
Can machine learning forecast Mineralys Therapeutics Inc. recoveryQuarterly Trade Review & Capital Efficient Trade Techniques - newser.com
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Why Mineralys Therapeutics Stock is Climbing Higher - TipRanks
Mineralys Therapeutics price target raised to $52 from $42 at H.C. Wainwright - TipRanks
HC Wainwright & Co. Maintains Mineralys Therapeutics (MLYS) Buy Recommendation - Nasdaq
Momentum divergence signals in Mineralys Therapeutics Inc. chartWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Mineralys Therapeutics Inc. stock recession proofJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - newser.com
12,300 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by Allianz Asset Management GmbH - MarketBeat
Is Mineralys Therapeutics Inc. stock a buy in volatile markets2025 Trading Volume Trends & Fast Entry High Yield Tips - Fundação Cultural do Pará
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):